Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00351676
• Other study ID #: EPICORE-2006-001
• Status: Completed
• Phase: Phase 4
• First received: July 12, 2006
• Last updated: December 7, 2007
• Start date: February 2006
• Est. completion date: July 2007

Study information

• Verified date: February 2006
• Source: University of Alberta
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Interventional

Clinical Trial Summary

We, the researchers, propose to link a clinical pharmacist with an internal medicine or family medicine team to provide pharmaceutical care to all patients assigned to the team. The hypothesis is that through this team based approach, pharmacists will act as a resource for providing pharmacotherapeutic advice during the drug therapy decision making process and promote optimal drug use by identifying and resolving actual and potential drug related problems. This study is designed to test this hypothesis, by assessing the impact of this intervention on evidence based, quality of drug therapy indicators, for patients admitted with heart failure (HF), chronic obstructive pulmonary disease (COPD), community acquired pneumonia (CAP), type 2 diabetes mellitus (T2DM), and stable coronary artery disease (CAD).

Description:

The overall goal of the COLLABORATE study is to improve processes of care and patient outcomes by optimizing drug therapy via a hospital pharmacy practice model that integrates clinical pharmacists into the patient care team.

The intervention consists of a clinical pharmacist assigned to the patient care team for the purpose of providing proactive clinical pharmacy services. The study pharmacist will be available during normal office hours 5 days per week to provide clarification of the patient's medication history, identify and resolve actual and potential patient specific drug related problems/issues, participate in patient care rounds, provide drug information to the patient care team, provide patient education and discharge medication counselling, and provide physician and/or nursing staff education. The anticipated pharmacist to patient ratio is approximately 1:20.

Control patients will receive usual care. Usual care consists of reactive clinical pharmacy services (i.e. drug related issues identified as orders are received, or by patient profile review) provided by a ward based, not team based, clinical pharmacist.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 452
• Est. completion date: July 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Consecutive patients > 18 years of age admitted to participating internal and family medicine teams during the 1 year study period will be eligible to receive the pharmacist intervention. For the purposes of data analysis, patients with a most responsible or primary diagnosis of HF, COPD, CAP, T2DM, and CAD will be included.

Exclusion Criteria:

• Residence outside the Capital Health catchment

• Admitted for = 2 days

• Palliative care

• Transferred to another team

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Arteriosclerosis
• Chronic Disease
• Coronary Arteriosclerosis
• Coronary Artery Disease
• Diabetes Mellitus, Type 2
• Heart Failure
• Heart Failure, Congestive
• Myocardial Ischemia
• Pneumonia
• Pulmonary Disease, Chronic Obstructive

Intervention

Behavioral:
• Integration of a team based clinical pharmacist

Drug:
• Optimizing therapeutic treatments

Behavioral:
• Optimizing processes of care

Locations

Country	Name	City	State
Canada	Grey Nuns Community Hospital	Edmonton	Alberta
Canada	Royal Alexandra Hospital	Edmonton	Alberta
Canada	University of Alberta Hospital	Edmonton	Alberta

Sponsors (2)

Lead Sponsor	Collaborator
University of Alberta	Capital Health, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement in proportion of quality indicators achieved, for target diseases as a most responsible or primary diagnosis, between groups.		in hospital	No
Secondary	Differences in condition-specific achievement of drug therapy quality indicators;		in hospital	No
Secondary	Differences in 6 month hospital readmission rate;		6 months	No
Secondary	Differences in number, type, acceptance rate, and expected impact of all pharmacist interventions;		in hospital	No
Secondary	Qualitative evaluation of the impact of the intervention via interviews with the participating pharmacists and physicians.		in hospital	No

External Links

•   Link